$KLTR

Azaria Eynav sold $15K of KLTR

Azaria Eynav (See Remarks) sold 10,702 shares of KALTURA INC (KLTR) at an average of $1.42 ($1.40–$1.43) across 2 trades over 2026-10-14 to 2026-10-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Azaria Eynav
Published Oct 16, 2026, 6:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 16, 2026, 6:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$KLTR
Neutral
high confidence
Mentioned
$KLTR
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KLTRNeutralLow
01

Why it matters

The disclosed event is an open-market sale of shares under a pre-arranged 10b5-1 plan. With proceeds around $15.2K, it is more likely to be informational for insider-tracking than a driver of price discovery.

02

Market read

Traders may monitor for patterns of insider selling, but this specific transaction is small and pre-planned, so it should not materially change the fundamental outlook by itself.

03

What to watch

Insider sales can be misread without context on total insider activity, option exercises, and whether other insiders are buying or selling around the same period.

Relevance 2/10Novelty 2/10Timing: filed 2026-10-16, covering sales dated 2026-10-14 to 2026-10-15

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for Kaltura (KLTR), reported by officer Azaria Eynav.

Company-level read

Ticker impact

$KLTRNeutralHigh confidence
Context

Insider Form 4 shows officer Azaria Eynav sold 10,702 shares of Kaltura (KLTR) for about $15.2K under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited near-term impact; any reaction would be more about interpreting insider selling than new fundamentals.

Evidence & confidence

The filing is an SEC Form 4 insider transaction, explicitly tied to a pre-arranged 10b5-1 plan, and the disclosed proceeds are modest versus typical market-moving thresholds.

Market effects

Minimal, as the disclosure is company-specific and not a sector-wide regulatory or operational change.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations, so traders may ignore it.

Key entities

  • Kaltura Inc

    Public company whose insider transaction is disclosed on Form 4.

  • Azaria Eynav

    Officer who sold 10,702 shares under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$KLTRMed

Kaltura Wins Best Event AI Technology at Eventex 2026 For the Fourth Straight Year

Kaltura (Nasdaq: KLTR) said it won “Best Event AI Technology” at the Eventex Awards for the fourth straight year. The company attributed the win to its Agentic Avatar event assistants, including real-time conversational features and analytics. Kaltura reported powering 9,000+ events for 1.3 million attendees, with 69% registration-to-attendance and 51% post-event participation.

$ASPEMedAI 8/10

ARCH Venture Fund X, L.P. (CRANDELL KEITH, Burow Kristina) purchased $18.0M of ASPE (indirect holdings)

ARCH Venture Fund X, L.P. purchased 1,200,000 indirectly-held shares of Aspen Neuroscience, Inc. (ASPE) at $15.00 ($18.00M total) on 2026-11-02. Filed jointly with ARCH Venture Fund X Overage, L.P. (10% owner), ARCH Venture Partners X, L.P. (10% owner), ARCH Venture Partners X Overage, L.P. (10% owner), ARCH Venture Partners X, LLC (10% owner), CRANDELL KEITH (10% owner), Burow Kristina (10% owner), GILLIS STEVEN (10% owner) and NELSEN ROBERT (10% owner).

$ASPELow

ARCH Venture Fund X, L.P. (CRANDELL KEITH, Burow Kristina) purchased $2.0M of ASPE

ARCH Venture Fund X, L.P. purchased 133,333 shares of Aspen Neuroscience, Inc. (ASPE) at $15.00 ($2.00M total) across 2 trades on 2026-11-02. Filed jointly with ARCH Venture Fund X Overage, L.P. (10% owner), ARCH Venture Partners X, L.P. (10% owner), ARCH Venture Partners X Overage, L.P. (10% owner), ARCH Venture Partners X, LLC (10% owner), CRANDELL KEITH (10% owner), Burow Kristina (10% owner), GILLIS STEVEN (10% owner) and NELSEN ROBERT (10% owner).